Results All the screening investigations were found to have a low yield, but the most sensitive were those for gamma-glutamyl transpeptidase (-yGT; sensitivity 21%) and alkaline phosphatase (sensitivity 25%), with )lGT being more specific (specificity 92%). No blood test had a positive predictive power greater than 50%. The chest radiograph and liver ultrasonography were both 100% specific but had sensitivities of 2% and 14%
seven per cent9 to 100%1 0 of patients who die from metastatic melanoma have evidence of liver involvement.
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The detection of metastatic spread at diagnosis of uveal melanoma does influence our management of this disease. In particular, we would avoid enucleation, if the eye was not painful, in patients with overt metastatic disease as we would consider that to be needless mutilation. Given the predisposition for spread to the liver, it is not surprising that screening This study was undertaken to determine the sensitivity, specificity, positive and negative predictive powers and the likelihood ratios of the commonly used screening tests.
Methods
The records of a series of patients with ciliary 
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Data were collected from the clinical notes, including age at diagnosis, sex, time to death or length of follow-up if alive, and site of tumour (ciliary body or choroidal).
Histological findings, where available, were categorised into spindle cell, mixed or epithelioid cell, and necrotic.
The investigations considered were the chest radiograph and blood investigations: haemoglobin, platelet and white cell counts, and levels of aspartate amino transferase (AST), alanine-amino transferase (ALT), gamma-glutamyl transpeptidase (-yGT), alkaline phosphatase (APH) and bilirubin (BIL). Liver ultrasonography is only performed routinely in our practice on patients due to undergo enucleation. It was also noted whether the patient had been staged by screening tests prior to referral to our unit, in order to obtain an estimate of referral bias.
Results
The records of 245 patients were retrieved, of whom 55 were dead, and 7 (7.5%) had necrotic melanoma of whom 4 (57.1%) had died from metastatic disease.
The chest radiograph was not available in 22 patients. The findings are summarised in Table 1, giving for each test the sensitivity, specificity, positive predictive power and negative predictive power. The positive predictive power of a test is the parameter of most use to a physician. Unfortunately, positive predictive power depends upon the incidence. Thus the predictive power of the tests depends on the nature of the population screened and the value obtained is therefore specific to that sample. There is no good single statistic that summarises how well a test performs, but the likelihood ratio (LR = sensitivity II-specificity) probably comes closest, and these results are also summarised in Table 1 .
If one knows the incidence of disease in the population, None had a sensitivity of greater than 25% and all had a significant false positive rate reducing the positive predictive power, for our sample, to 50% or less.
The white cell count was surprisingly specific for metastatic disease (98%) but had low sensitivity (7%). All the other haematological results proved to be of no value in screening for disseminated disease. The imaging tests fare better. Both the chest radiograph and liver ultrasonography were 100% specific but the yields are poor, with sensitivities of only 2% for the chest radiograph and an even more disappointing 14% for liver ultrasonography (considering that it was only performed on relatively high-risk cases).
There are several potential ways that these screening tests could be improved. One way in which the blood tests may be improved is to analyse the results not singly but together. If we take it that a combination of both a positive ALT result and either a positive 'YGT or a positive APH are required for a patient to be considered positive for screening, then the specificity rises to over 99% for our sample, but the sensitivity falls to only 7%.
We also have to be cautious about constructing such systems for retrospective data, as they often do not To summarise, the only single tests specific enough to be useful were imaging by chest radiography and liver ultrasonography, and we now carry out these investigations routinely on all melanoma patients before treatment. No single blood test was useful, due to a combination of poor specificities and sensitivities. It was possible to improve the specificity by combining blood results but this was at the expense of reduced sensitivity.
We conclude that, for our sample, only a small proportion of metastatic disease was detectable at presentation.
